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Abstract 
A new method, based on the ion-translocating properties of the ionophores nigericin and A23187, is described for loading 
large unilamellar vesicles (LUVs) with the drugs vincristine and ciprofloxacin. LUVs composed of distearoylphos- 
phatidylcholine/cholesterol (DSPC/Chol) (55:45 mol/mol) or sphingomyelin (SPM)/Chol (55:45 mol/mol) exhibiting a 
transmembrane salt gradient (for example, internal solution 300 mM MnSO4 or K2SO4; external solution 300 mM sucrose) 
are incubated in the presence of drug and, for experiments involving divalent cations, the chelator EDTA. The addition of 
ionophore couples the outward movement of the entrapped cation to the inward movement of protons, thus acidifying the 
vesicle interior. External drugs that are weak bases can be taken up in response to this induced transmembrane pH gradient. 
It is shown that both nigericin and A23187 facilitate the rapid uptake of vincristine and ciprofloxacin, with entrapment levels 
approaching 100% and excellent retention i vitro. Following drug loading, the ionophores can be removed by gel exclusion 
chromatography, dialysis, or treatment with biobeads. In vitro leakage assays (addition of 50% mouse serum) and in vivo 
pharmacokinetic studies (in mice) reveal that the A23187/Mn 2÷ system exhibits uperior drug retention over the nigericin/K + 
system, and compares favorably with vesicles loaded by the standard ApH or amine methods. The unique features of this 
methodology and possible benefits are discussed. © 1998 Elsevier Science B.V. All rights reserved. 
Keywords." Drug loading; pH gradient; Ionophore; A23187; Nigericin; Ciprofloxacin; Vincristine; Manganese; Divalent cation 
1. Introduction 
The ability of transmembrane pH gradients (ApH) 
to influence the equilibrium transmembrane distribu- 
tions of certain weak acids and weak bases has long 
been recognized ([1], and Refs. therein). Recent work 
from this laboratory has demonstrated the transbi- 
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layer movement of a wide variety of drugs, biogenic 
amines, amino acids, peptides, lipids, and ions in 
large unilamellar vesicles (LUVs) exhibiting a ApH 
(for a review, see [1]). This technology can be em- 
ployed to load liposomes with drugs such as the anti- 
cancer agents doxorubicin and vincristine, resulting 
in significantly reduced toxicity and equal or in- 
creased efficacy for the liposomally encapsulated for- 
mulations [2-13]. 
The pH gradient methodology has distinct advan- 
tages over other methods of encapsulation. These 
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include high trapping efficiencies (90-100%), high 
drug-to-lipid ratios, and greatly improved drug re- 
tention in vivo. The basic pH gradient-loading tech- 
nique involves formation of the LUVs by extrusion 
in an appropriate buffer (e.g., 300 mM citrate pH 
4.0), followed by formation of the pH gradient on 
a Sephadex column equilibrated in HEPES/NaC1 pH 
7.5. Other pH gradient-loading techniques include 
those involving LUVs exhibiting transmembrane gra- 
dients of ammonium sulfate [14-17] or other amines 
(including methylammonium sulfate, ethylammo- 
nium sulfate, propylammonium sulfate, amylammo- 
nium sulfate, and several diamines) [18]. The amine 
gradient gives rise to a secondary pH gradient, which 
drives drug uptake. 
This paper describes a new method for loading 
LUVs with drugs which exhibit weak base character- 
istics. We build on an observation first made by 
Deamer [19] some 25 years ago, that addition of 
nigericin to SUVs containing potassium salts led to 
the generation of a pH gradient (interior acidic) of 
approx. 2 units. We apply this process for iono- 
phores such as nigericin or A23187 to LUVs exhibit- 
ing transmembrane gradients of K + or Mn2+(Mg2+), 
respectively. The outward movement of the metal 
ions (down their concentration gradients) results in 
the acidification of the LUV interior, which drives 
drug uptake. We show that rapid uptake and excel- 
lent retention can be obtained for both vincristine 
and ciprofloxacin using both ionophores, and that 
reasonable in vivo clearance characteristics are 
achieved using the A23187 formulation. 
2. Materials and methods 
2.1. Materials 
DSPC was obtained from Northern Lipids (Van- 
couver, B.C., Canada). Egg SPM, cholesterol (Chol), 
nigericin, and A23187 were obtained from Sigma. 
Vincristine sulfate was obtained from Eli Lilly Can- 
ada (Scarborough, Ont., Canada) or from Pharmacia 
(Mississauga, Ont., Canada), and [3H]vincristine 
from Amersham (Oakville, Ont., Canada). Ciproflox- 
acin and [14C]ciprofloxacin were obtained from Inex 
Pharmaceuticals. [3H]Cholesterol hexadecyl ether 
(CHE) and [14C]CHE were obtained from Dupont 
New England Nuclear. Normal mouse serum was 
obtained from Cedar Lane Laboratories (Hornby, 
Ont., Canada). All other chemicals were reagent 
grade. 
2.2. Preparation of large unilamellar vesicles 
DSPC/Chol and SPM/Chol (55:45 mol/mol) lipid 
mixtures, containing a trace of either [14C]CHE or 
[3H]CHE, were prepared by lyophilization from 
t-butanol. The lipid film was hydrated in the salt of 
choice at 60°C and subjected to five cycles of freeze- 
thawing using liquid nitrogen and water at 60°C, 
with vigorous vortexing of the lipid between each 
thaw and freeze cycle. LUVs were prepared by ex- 
truding the lipid emulsion through polycarbonate fil-
ters with a 0.1 ~tm pore size under high pressure 
(300-400 psi) at 60°C [20]. Lipids were hydrated 
with a variety of salt solutions, including K2SO4, 
KH2PO4, K2HPO4, K-tartrate, CaC12, MnSO4, and 
MgSO4. The salt concentrations were 300 mM or 600 
mM; for some experiments the pH was adjusted, 
usually in the range of 6-7.5. 
2.3. Formation of salt gradient 
LUVs exhibiting a transmembrane salt gradient 
were prepared by solvent exchange using columns 
of Sephadex G-50 (1.5×10 cm) pre-equilibrated 
with 300 mM sucrose. Salt gradients were also estab- 
lished by gel filtration chromatography using spin 
columns [21], in which the equilibrated G-50 gel is 
packed into a 1 ml disposable syringe by centrifuga- 
tion to 760×g. To establish the gradient, 50-100 ~tl 
aliquots of the LUVs are applied to each spin col- 
umn and centrifuged at 760 × g on a desktop centri- 
fuge for 2 min. In a few cases, the gradient was 
formed by dialysis. 
2.4. Uptake of ciprofloxacin and vincristine 
For both drugs, uptake was performed at 60°C at 
a total lipid concentration of 5 mM (1 ml). For ci- 
profloxacin, the initial drug-to-lipid ratio was either 
0.2 or 0.3 (mol/mol), and for vincristine the initial 
drug-to-lipid ratio was 0.03 (mol/mol). For uptake 
via nigericin in response to K ÷ gradients, the LUVs 
and drug were combined and incubated for a period 
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of 15 min at 60°C. An aliquot (100 ~tl) was removed 
in order to determine the initial drug-to-lipid ratio, 
and a further aliquot (50-100 ~tl) was passed down a 
spin column to assess any uptake prior to addition of 
the ionophore. The nigericin (dissolved in EtOH) was 
then added (approx. 5 ~tl volume) to the suspension 
to give the desired concentration (ranging from < 1 
ng/~tmol lipid to 1 ~tg/Ixmol lipid). At various times, 
aliquots of the suspension were removed and applied 
to spin columns, with the eluant analyzed by dual 
label counting to monitor uptake of the drug (see 
below). The procedure for A23187-dependent drug 
uptake in response to gradients of divalent cations 
was essentially the same, except that in most cases 
EDTA was added to the external buffer to give a 
final concentration of 3-15 mM. 
2.5. Drug leakage in response to mouse serum 
An in vitro assay was chosen to give a qualitative 
comparison of the leakage of different drugs from 
the ionophore systems. Essentially, equal volumes 
of the liposomal drug formulation and of mouse se- 
rum were combined in a test tube and incubated at 
37°C. Leakage of the drug from the LUVs was as- 
sayed by removal of aliquots for spin column analy- 
sis. 
2.6. Drug and lipid assays 
Ciprofloxacin concentrations were determined by 
measuring the absorbance at 275 nm following dis- 
ruption of the vesicles and solubilization of the drug 
by a modified Bligh and Dyer extraction procedure 
[20]. Vincristine concentrations were determined by 
measuring the absorbance in 80% ethanol at 295 nm 
[22]. [14C]Ciprofloxacin was diluted with cold cipro- 
floxacin and the specific activity determined by liquid 
scintillation counting and absorbance spectroscopy. 
The specific activity of [3H]vincristine was deter- 
mined in the same manner. For experiments involv- 
ing [14C]ciprofloxacin, the lipid mixtures were labeled 
using trace amounts of [3H]CHE. For [3H]vincristine 
uptake the lipid was labeled with [14C]CHE. Lipid 
specific activities were determined by liquid scintilla- 
tion counting and by quantification of phospholipid 
via phosphate assays [23]. For all uptake experi- 
ments, drug-to-lipid ratios were determined by dual 
label liquid scintillation counting. These were com- 
pared with drug-to-lipid ratios obtained by chemical 
and spectrophotometric assays and found to be iden- 
tical. 
2. 7. Fluorimetric assay for A23187 
The quantity of A23187 in SPM/Chol LUVs was 
determined by measuring the fluorescence intensity 
of the ionophore at an emission wavelength of 437 
nm following solubilization of the liposomal formu- 
lation and complexation of the released ivalent cat- 
ions. Briefly, an aliquot of LUV/A23187 (corre- 
sponding to 5 ~tmol total lipid) was combined with 
a 333 mM EDTA solution (3 ~1) and the volume was 
made up to 1 ml with ethanol:methanol (70:30 v/v). 
The sample was vortexed until clear, and the fluores- 
cence intensity measured. Calibration standards were 
prepared by the addition of known aliquots of 
A23187 to a 1 ml solution consisting of ethanol:me- 
thanol (70:30 v/v) and containing 5 mM total lipid. 
2.8. In vivo pharmacokinetics 
SPM/Chol LUVs (100 nm diameter) were used 
(55:45 mol/mol). The vesicles were prepared in a 
300 mM MnSO4 solution and the external medium 
was exchanged with 300 mM sucrose by overnight 
dialysis. Ciprofloxacin was loaded at a drug-to-lipid 
ratio of 0.2 (mol/mol) and vincristine was loaded at a 
drug-to-lipid ratio of 0.03 (mol/mol). Drug uptake 
was accomplished by addition of 0.1 I-tg A23187/ 
~tmol ipid, followed by an aliquot of EDTA pH 7 
(to give a final concentration of 30 mM) and the 
appropriate amount of drug. The resulting solution 
was heated at 65°C for 30 min for ciprofloxacin or 
15 min for vincristine. 
Each sample was passed down a Sephadex G-50 
column (to remove xternal drug and ionophore) and 
diluted with 300 mM sucrose to allow for a drug 
dose in mice of 15 mg/kg for ciprofloxacin or 2 mg/ 
kg for vincristine. Each mouse was injected via a 
lateral tail vein with 200 ~tl total volume. ICR mice 
were used for the ciprofloxacin studies and BDF-1 
mice were used for the vincristine studies. At varying 
time points, mice were anesthetized (ketamine, xyla- 
zine) and blood was collected via cardiac puncture. 
Blood was immediately centrifuged at 500 ×g and 
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Fig. l. Chemical structures of ciprofloxacin (pE] = 6.0, 
pK2 = 8.8) (A) and vincristine (pK] = 5.0, pK2 -- 7.4) (B). 
plasma was collected for lipid and drug determina- 
tion by dual label scintillation counting. 
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Fig. 2. Diagrammatic representation of ionophore-dependent 
drug loading, exemplified for the MnZ+/A23187 system. LUVs 
are hydrated and subsequently extruded in 300 mM MnSO4, 
following which Mn 2~ ions (represented as e) are present in 
roughly equal concentrations within the vesicles and in the ex- 
ternal medium (top). A Mn 2+ ion gradient is established by 
passage of the LUVs down a column of Sephadex G-50 hy- 
drated in 300 mM sucrose (which may be buffered) (center). 
Gradient formation can also be accomplished using spin col- 
umns or by dialysis. The remote loading process involves addi- 
tion of drug, EDTA, and A23187 to the LUVs exhibiting the 
ion gradient. The drug and EDTA can be added prior to the 
ionophore or they can be added simultaneously (see text for 
more details). A23187 is an electroneutral transporter, which 
couples the external transport of one Mn 2+ ion (down its con- 
centration gradient) to the internal transport of two protons. 
This process results in acidification of the vesicle interior, creat- 
ing a ApH of 3 units. The external drug exists in neutral and 
protonated forms, and it is the former which can diffuse across 
the membrane (down its concentration gradient). Once inside 
the vesicle, they are protonated and trapped, resulting in an ex- 
tremely low internal concentration of neutral drug, which there- 
fore continues to drive uptake. In order for this process to oc- 
cur, an external chelator such as EDTA is required to bind 
Mn 2+ ions as they are transported out of the vesicle, thereby 
maintaining a sufficient gradient of the free ion. The process is 
similar for the ionophore nigericin, which catalyzes the electro- 
neutral transport of one K + for one H +, except that a K + salt 
is required, and an external chelator is not required to achieve 
good uptake of drug. For clarity, solutes such as sulfate anions, 
sucrose, and buffers are not shown. In addition, the A23187 
transport mechanism is not shown in detail. For more details, 
see the text and [24]. 
3. Results 
The chemical structures of ciprofloxacin and vin- 
cristine are shown in Fig. 1 ; their pK values are given 
in the figure legend. Ciprofloxacin is a quinolone 
antibiotic widely used in the treatment of respiratory 
and urinary tract infections. Recent work indicates 
that liposomal formulations are more effective in 
protecting mice from infection and provide greater 
efficacy in treating infected mice than the free drug 
[24]. Vincristine, a Vinca alkaloid derived from the 
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periwinkle plant, is an important anticancer drug ef- 
fective against a wide variety of neoplasms [25,26], 
which exhibits significantly enhanced efficacy in lip- 
osomal form [6-8,27]. Both drugs present challenges 
with respect to the development of liposomal formu- 
lations. Ciprofloxacin is a zwitterionic compound 
that is nearly insoluble in its net neutral or un- 
charged forms, which occur in the range near phys- 
iological pH (pH 6-8), and is poorly retained in 
vesicles [14]. Vincristine has two pK values, and ex- 
hibits poor retention within vesicles unless the inter- 
nal pH is very low (pH 2) [6-8]. 
The general principles behind ionophore-depend- 
ent drug uptake are illustrated in Fig. 2. LUVs are 
formed which entrap a high concentration f a metal 
ion such as K + or Mn 2+, and an ion gradient is 
established by removal of the external metal ion 
(Fig. 2, top and center). Drug is added to the exter- 
nal medium, and uptake is initiated by addition of an 
ionophore which couples the outward transport of 
the metal ion to the inward movement of H +. This 
creates a pH gradient (inside acidic) which results in 
uptake of compounds with weak base characteristics, 
such as the drugs ciprofloxacin and vincristine. The 
ionophore nigericin catalyzes a one-for-one xchange 
of K + for H +, whereas A23187 transports 2H + for 
every M 2+ (where M = Ca, Mn, or Mg) [28-30]. Both 
processes are electroneutral [29,30]. As described be- 
low, both ionophores are capable of generating pH 
gradients of 2-3 units. 
Although the general principle is straightforward, 
a number of parameters need to be varied in order to 
achieve optimal drug uptake. These include lipid 
composition, internal salt concentration, the iono- 
phore to lipid ratio, and the pH of the internal and 
external solutions. In addition, systems containing 
divalent cations may require an external chelator to 
drive uptake to completion (Fig. 2, bottom). Exam- 
ples involving the ionophores nigericin and A23187 
are described below, with the optimized conditions 
for uptake summarized in Tables 1 and 2. 
3.1. Nigericin-dependent up ake of ciprofloxacin 
The uptake of ciprofloxacin in DSPC/Chol (55:45) 
LUVs containing 300 mM K2SO4 is illustrated in 
Fig. 3A. The external medium was 300 mM sucrose. 
Little or no drug uptake occurred in response to the 
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Fig. 3. (A) Effect of nigericin concentration on the uptake of ci- 
profloxacin in 100 nm DSPC/Chol LUVs containing 300 mM 
K2SO4. The nigericin was present at 1 Ixg/Ixmol ipid (o) or at 
0.01 ng/pmol lipid (l). No uptake of drug occurred prior to 
the addition of nigericin, which is indicated by the arrow. The 
initial drug-to-lipid ratio was 0.3, and the uptake temperature 
was 60°C. (B) Effect of nigericin concentration on the uptake 
of ciprofloxacin in 100 nm DSPC/Chol LUVs containing 600 
mM K2SO4. The nigericin was present at 0.1 lxg/~mol lipid 
(• ) ,  at 1 ng/~tmol lipid (l), or at 0.1 ng/tamol lipid (o; dotted 
line). No uptake of drug occurred prior to the addition of ni- 
gericin, which is indicated by the arrow. The initial drug-to-lip- 
id ratio was 0.3~).37, and the uptake temperature was 60°C. 
K + gradient alone, whereas within 5 min of addition 
of nigericin (indicated by the arrow) at a concentra- 
tion of 1 p.g/~tmol lipid, 80% uptake was observed. 
The process was extremely rapid, giving high entrap- 
ment levels within minutes, with excellent retention 
observed over 3 h at 60°C. The observed uptake was 
not influenced by increasing the internal salt concen- 
tration to 600 mM (Fig. 3B). 
The rapid uptake observed in Fig. 3A suggested 
that lower ionophore levels would be equally as ef- 
fective. For LUVs containing 300 mM K2SO4, re- 
ducing the nigericin concentration by a factor of 
105 (to 0.01 ng nigericin/~tmol lipid) resulted in 
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Table 1 
Optimized a conditions for drug loading experiments using nigericirdK + systems 
193 
Lipid composition I ternal salt b DIL c I lL d % uptake T (°C) External solution: 300 mM sucrose+ 
( A ) Ciprofloxacin 
DSPC/Chol K2SO4 0.3 1000 80 60 
DSPC/Chol 600 mM K2SO4 0.3 100 80 60 
DSPC/Chol 600 mM K2SO4 0.3 1 80 60 
DSPC/Chol 600 mM K2SO4 0.37 0.1 85 60 
SPM/Chol K2SO4 pH 7.4 0.2 1 80 60 
SPM/Chol KzSO4 pH 6.1 0.2 1 90 60 
SPM/Chol K2SO4 pH 6.1 0.2 1 100 60 
SPM/Chol K2SO4 pH 6.1 0.2 0.5 100 70 
(B) Vincristine 
DSPC/Chol K2-tartrate pH 7.4 0.05 1 85-90 60 
SPM/Chol K2SO4 pH 7.4 0.05 1 92 60 
SPM/Chol KHzPO4 0.05 1 80 60 
20 mM HEPES pH 7.0 
20 mM HEPES pH 7.0 
20 mM HEPES pH 6.2 
20 mM HEPES pH 5.5 
20 mM HEPES pH 5.3~5.3 
20 mM HEPES or MES pH 6.0 
aDefined as -> 80% uptake, with leakage of < 5% over 2 h. 
b300 mM unless otherwise indicated. 
¢Initial drug-to-lipid ratio, given in (mol/mol) for ciprofloxacin, and (w/w) for vincristine. 
dIonophore/lipid ratio (ng nigericin/~tmol lipid). 
only 12% uptake over 80 min (Fig. 3A). For LUVs 
containing 600 mM K2SO4, no change in uptake was 
observed following reduction of the ionophore con- 
centration by a factor of 103 (to 1 ng nigericin/~maol 
lipid) (Fig. 3B). However, a 10a-fold reduction re- 
suited in a significant decrease in the rate of uptake 
of ciprofloxacin (Fig. 3B), with at least 45 min re- 
quired to obtain uptake levels of 80% or greater. 
Thus a nigericin concentration of 1 ng/~tmol lipid 
was chosen to obtain optimal oading levels within 
a reasonable time span. It will be seen later that 
under appropriate conditions this can be reduced to 
0.5 ng nigericirdlxrnol lipid. 
The initial experiments described above were per- 
formed using DSPC/Chol LUVs, a composition giv- 
ing rise to stable, highly ordered (and therefore rel- 
atively impermeable) vesicles, which have been 
utilized in formulations of vincristine and doxorubi- 
cin [2,4,6,7]. Recently, a superior vincristine formu- 
lation was achieved using SPM/Chol (55:45) LUVs 
in conjunction with the standard pH gradient-load- 
ing technique [8,27]. In order to assess the use of 
Table 2 
Optimized a conditions for drug loading experiments using A23187 systems 
Lipid composition Internal salt b DIL c IlL d % uptake T (°C) External solution: 300 mM sucrose+ 
( A) Ciprofloxacin 
DSPC/Chol MnSO4 0.27-0.35 0.1 95 60 
SPM/Chol MnSO4 0.2 0.1 70-80 60 
SPM/Chol MnSO4 0.2 0.1 98 60 
SPM/Chol MgSO4 pH 6.5 0.2 0.1 80 60 
SPM/Chol MgSO4 pH 6.5 0.2 0,1 80 60 
SPM/Chol MgSO4 pH 6.5 0.2 0,1 86 60 
SPM/Chol MgSO4 pH 6.5 0.2 0,5 97 60 
( B) Vincristine 
SPM/Chol MnSO4 0.05 0,1 > 95 60 
3 mM EDTA 
15 rnM EDTA pH 4.4 
15 mM EDTA pH 5.9 
15 mM EDTA pH 7.0 
20 mM HEPES 15 mM EDTA pH 7.0 
20 mM HEPES 15 mM EDTA pH 6.0 
20 rnM HEPES 15 mM EDTA pH 6.0 
20 mM HEPES 3 mM EDTA pH 7.5 
aDefined as --> 80% uptake, with leakage of < 5% over 2 h. 
b300 mM unless otherwise indicated. 
Clnitial drug-to-lipid ratio. 
alonophore/lipid ratio (~tg A23187/~tmol lipid). 
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Fig. 4. Optimized conditions for the uptake of ciprofloxacin in 
100 nm SPM/Chol LUVs containing 300 mM K2SO4 pH 6.1. 
For the uptake at 60°C, the nigericin was present at 1 ng/Jamol 
lipid, and the external medium was 300 mM sucrose 15 mM 
EDTA pH 6.2 (m). For the uptake at 70°C, the nigericin was 
present at 0.5 ng/I.tmol lipid, and the external medium was 300 
mM sucrose 15 mM EDTA pH 5.5 (o). The nigericin was 
added at time 0. The initial drug-to-lipid ratio was 0.2. 
SPM/Chol LUVs in the present study, we have ex- 
amined the uptake of ciprofloxacin (and vincristine) 
using both nigericin and A23187 (below). To stand- 
ardize our experiments, we chose a basic system con- 
sisting of 100 nm SPM/Chol (55:45) LUVs contain- 
ing 300 mM K2SO4,  an  initial drug-to-lipid ratio of 
0.2, and an ionophore concentration of 1 ng niger- 
icin/~tmol lipid. 
Optimum uptake was obtained for an (initial) in- 
ternal pH of 6.1 and an external pH of 6.2 (HEPES- 
buffered sucrose), with 100% uptake achieved after 
60 min at 60°C (Fig. 4). The same result was ob- 
tained at 70°C when the ionophore concentration 
was reduced to 0.5 ng nigericin/~tmol lipid (for an 
external pH of 5.5), although 90 min were required 
to achieve 100% uptake (Fig. 4). Raising either the 
external or internal pH reduced the uptake (e.g., only 
80% uptake for internal and external pH values near 
7.0). Thus, the SPM-containing vesicles are equiva- 
lent to or better than the DSPC-containing vesicles in 
terms of uptake levels, but require longer loading 
times. Whereas the DSPC/Chol LUVs are fully 
loaded within 5 min, the SPM/Chol LUVs achieve 
maximum uptake only after 30-60 min. 
3.2. Nigericin-dependent up ake of vincristine 
Using the same basic system described above, the 
uptake of vincristine (drug-to-lipid ratio = 0.03 moll 
mol) was determined as a function of internal and 
external pH. High uptake levels (93-95% uptake) 
were obtained for pHi = 7.4 and pHo = 6 (see Fig. 
7B). For pHo = 7.5, the uptake was low (only 60%), 
with poor retention over 75 min (not shown). Rea- 
sonable encapsulation of vincristine (80%) was also 
observed for LUVs containing 300 mM KH2PO4 
(not shown). 
Uptake of vincristine in response to transmem- 
brane gradients of K2-tartrate has also been investi- 
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Fig. 5. (A) Effect of external EDTA on the uptake of ciproflox- 
acin in 100 nm DSPC/Chol LUVs containing 300 mM MnSO4. 
The external medium was 300 mM sucrose 3 mM EDTA (11) or 
300 mM sucrose (o). The addition of A23187 (0.1 Bg/~tmol lip- 
id) is indicated by the arrow. The uptake temperature was 
60°C, and the initial drug-to-lipid ratio was 0.35 (mol/mol). (B) 
Effect of external pH and ionophore concentration on the up- 
take of ciprofloxacin in 100 nm SPM/Chol LUVs containing 
300 mM MgSO4 pH 6.5. For 0.1 ~g A23187/~mol lipid, the ex- 
ternal medium was 20 mM HEPES 300 mM sucrose 15 mM 
EDTA pH 7.0 (l), 300 mM sucrose 15 mM EDTA pH 7.0 
(0) ,  300 mM sucrose 15 mM EDTA pH 4.4 (o), or 20 mM 
HEPES 300 mM sucrose 15 mM EDTA pH 6.0 (©). For 0.5 
~tg A23187/~tmol lipid, the external medium was 20 mM 
HEPES 300 mM sucrose 15 mM EDTA pH 6.0 ([]). The sam- 
ples were placed in a water bath at 60°C at t=-5  min, and the 
A23187 was added at time 0. The initial drug-to-lipid ratio was 
0.2 (mol/mol). 
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gated in DSPC/Chol LUVs (Table 1), with values of 
85-90% obtained within 15 min at 60°C using 300 
mM K2-tartrate pH 7.4 as the internal salt, and 
HEPES-buffered sucrose pH 5.3-6.3 as the external 
medium. Under these conditions, a ApH of 2.3, 
measured using [14C]methylamine [31], was present 
following drug uptake. This is in agreement with 
early data of Deamer and coworkers, who found 
that nigericin could induce a pH gradient of 2.2 units 
across sonicated vesicle membranes [19]. For pur- 
poses of comparison, vincristine uptake was also per- 
formed using LUVs containing 300 mM ammonium 
sulfate [16], with all other conditions the same (data 
not shown). The results were identical, indicating 
that the ionophore and ammonium sulfate methods 
give equivalent results as far as drug uptake is con- 
cerned. 
Vincristine uptake in response to K2-tartrate was 
also examined in SPM/Chol LUVs, but only 70% 
uptake was achieved (data not shown). 
100 
80 
60 
40 
20 
0 
0 30 60 90 
Time (min) 
Fig. 6. Effect of external pH and EDTA on the uptake of vin- 
cristine in 100 nm SPM/Chol LUVs containing 300 mM 
MnSO4. The external medium was 20 mM HEPES 300 mM su- 
crose 3 mM EDTA pH 7.5 (11), 300 mM sucrose 3 mM EDTA 
pH 6 (0),  or 20 mM HEPES 300 mM sucrose pH 7.5 (o). The 
addition of A23187 (0.1 I.tg/~tmol lipid) is indicated by the ar- 
row. The uptake temperature was 60°C, and the initial drug-to- 
lipid ratio was 0.03 (mol/mol). 
3.3. A23187-dependent uptake of ciprofloxacin 
The carboxylic ionophore A23187 transports diva- 
lent cations across membranes with specificity 
Mn 2+ > Ca 2÷ > Mg 2÷ and relative binding affinities 
of 210:2.6:1, respectively [28]. Calcium salts tend to 
be relatively insoluble, and the major exception 
(CaC12) suffers from the high membrane solubility 
of neutral HCI, which contributes to the loss of 
any induced pH gradient. Preliminary ciprofloxacin 
uptake xperiments u ing DSPC/Chol LUVs contain- 
ing 300 mM CaC12 gave low encapsulation levels 
(40%) and poor retention (not shown). Therefore 
we turned our attention to salts of Mn 2+ and 
Mg 2÷, with particular attention to the former in light 
of its significantly higher elative binding affinity for 
A23187. 
Fig. 5A details the uptake of ciprofloxacin in re- 
sponse to gradients of 300 mM MnSO4. The effect of 
both ionophore and external EDTA are shown for 
uptake of ciprofloxacin (initial drug-to-lipid ra- 
tio=0.35) into DSPC/Chol (55:45) LUVs at 60°C. 
At time t = 0 min, the LUVs and ciprofloxacin were 
combined and placed in a water bath at 60°C. As 
MnSO4 solutions are acidic (pH 3-4), it was expected 
that some uptake would be observed prior to the 
addition of the A23187, and this was in fact ob- 
served. At 45 min, about 35% uptake was observed 
in the sample without EDTA, and about 18% in the 
EDTA-containing sample. In the latter case, the 
EDTA lowers the external pH and therefore ApH, 
which accounts for the lower uptake (the uptake is 
also pH dependent, asdiscussed below). These values 
are close to the maximum uptake observed without 
ionophore. At t = 47 min, A23187 was added to give 
a final concentration f 0.1 ~tg/~trnol lipid (arrow). In 
the absence of external EDTA, a further small up- 
take to about 55% occurred, which was stable over a 
period of 3 h. In the presence of external EDTA, 
further uptake of ciprofloxacin, to a final level 
> 90%, occurred over a period of 45 min. This was 
increased to 95% by reducing the initial drug-to-lipid 
ratio to 0.27 (Table 2). Thus, even with an acidic 
internal salt solution, the ionophore is necessary to 
obtain high uptake values. Furthermore, the presence 
of an external chelator such as EDTA is essential to 
drive this process. This requirement for EDTA can 
be understood from a simple equilibrium model for 
drug uptake (see below). Under the conditions de- 
scribed here, the ionophore A23187 in the presence 
of external EDTA will generate a z~pH of 3 units 
(B. Cheung, unpublished results). 
The uptake of ciprofloxacin into SPM/Chol 
(55:45) LUVs was also investigated (data not 
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100 A f loxacin, v ia niger ic in and  A23187, appears  to be 
\ around 6. 
a0 Excel lent  encapsu la t ion  o f  c iprof loxac in  can also 
be achieved using gradients  o f  MgSO4 ( internal  
60 salt = 300 mM MgSO4 pH 6.5, external  me- 
15 d ium = 300 mM sucrose mM EDTA) ,  as shown 
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Fig. 7. (A) Uptake of ciprofloxacin i  100 nm SPM/Chol LUVs o~, -/~
at 60°C and its retention in the presence of 50% mouse serum 20 
at 37°C. Uptake experiments were performed for the following 
combinations of ionophore/internal salt: A23187/MnSO4 (e), 0 
A23187/MgSO4 (l), nigericin/K2SO4 (0). The arrow indicates 
the addition of mouse serum (to a final concentration of 50%) 
and transfer of the sample to 37°C. (B) Uptake of vincristine in 
100 nm SPM/Chol LUVs at 60°C and its retention in the pres- 
ence of 50% mouse serum at 37°C. Uptake experiments were 
performed for the following combinations of ionophore/internal 
salt: A23187/MnSO4 (o), nigericin/K2SO4 (O), nigericin/K2SO4 
(pHi=7.4, pHo =6.0) ((>). For the latter two preparations, 
both the internal and external pH values (pHi and pHo, respec- 
tively) were adjusted prior to uptake, and the external solution 
was 20 mM MES 300 mM sucrose pH 6.0. All internal salts 
were present at 300 mM. The arrow indicates the addition of 
mouse serum (to a final concentration of 50%) and transfer of 
the sample to 37°C. 
shown),  and  as above,  low uptake  (30%) was ob-  
served in the absence o f  EDTA.  In  the presence o f  
EDTA,  the final ent rapment  levels were dependent  
on the external  pH.  On ly  80% uptake  was observed 
at pHo =4.4 ,  but  this was increased to 98-100% at 
pHo = 5.9. The pH opt imum for the uptake  o f  c ipro-  
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Fig. 8. Removal of nigericin from SPM/Chol LUVs as assayed 
by drug uptake. (A) Effect of spin columns on uptake of cipro- 
floxacin at 60°C. Uptake was monitored for LUVs containing 
300 mM K2804 at a nigericin concentration of 1 ng/Ixmol ipid 
(I), and for LUVs which were preincubated with nigericin for 
5 min at 60°C, and then passed down a spin column prior to 
addition of the drug (o). (B) Effect of dialysis on uptake of vin- 
cristine by ionophore and amine methods at 60 and 65°C. 
LUVs (1-2 ml) containing 300 mM KH2PO4 (0,<)), 300 mM 
ethylammonium sulfate (l,[]), or 300 mM amylammonium sul- 
fate (A, zx) were dialyzed exhaustively (3 ×2 1) overnight at 
room temperature against 300 mM sucrose. Vincristine was 
then added and uptake assessed. The closed symbols refer to 
uptake at 60°C and the open symbols to uptake at 65°C. For a 
comparison, the ion gradient of one LUV sample containing 
EAS was formed using a Sephadex G-50 column ([] and dotted 
line). The experiments with EAS and AAS were performed to 
ensure that there was no loss of vesicle contents during the di- 
alysis period. 
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in Fig. 5B. The lipid composition and uptake temper- 
ature are given in the figure legend. For A23187 con- 
centrations of 0.1 ~g/~tmol lipid, maximal uptake val- 
ues (86%) were observed at pHo=6.0 (20 mM 
HEPES+sucrose-EDTA). For these conditions, in- 
creasing the A23187 concentration 5-fold (to 0.5 
~tg/~trnol lipid) resulted in 97% entrapment. This is 
equivalent to the MnSO4 results, aside from the ne- 
cessity of using higher ionophore concentrations. A 
summary of these results is given in Table 2. 
3.4. A23187-dependent uptake of vincristine 
Excellent uptake and retention of vincristine can 
also be obtained using Mn2+/A23187 with SPM/Chol 
LUVs (Fig. 6). Less than 5% uptake was observed 
when EDTA was lacking in the external medium of 
HEPES-buffered sucrose pH 7.5. In the presence of 
3 mM EDTA (pHo=7.5), over 95% uptake was ob- 
served within an hour. A summary of these results is 
given in Table 2. 
3.5. In vitro leakage assays: release of ciprofloxacin 
and vincristine from L UVs in response to mouse 
serum 
A simple in vitro leakage assay employing mouse 
serum was developed to assess the relative retentive 
properties of the various liposomal systems (see Sec- 
tion 2). The release of ciprofloxacin from SPM/Chol 
LUVs resulting from incubation in 50% mouse serum 
at 37°C is shown in Fig. 7A. The best retention of 
drug was observed for the Mn2+/A23187 system 
(60% remaining after 2 h), followed by the Mg2+/ 
A23187 system (35%) and finally by the K+/nigericin 
system. The much more rapid loss of material from 
LUVs containing nigericin may result from the pres- 
Table 3 
Fluorimetric determination of A23187 in a liposomal formulation 
ence of K ÷ in serum, which would cause reverse 
transport and reduce or collapse the pH gradient. 
The release of vincristine from SPM/Chol LUVs 
resulting from incubation in 50% mouse serum at 
37°C is shown in Fig. 7B. As with ciprofloxacin, 
better retention of drug was observed for the 
Mn2+/A23187 system than for the K+/nigericin sys- 
tem. In the latter case, better etention was observed 
using phosphate or tartrate salts (not shown), or us- 
ing sulfate salts with an external pH of 6. The reten- 
tion observed with the Mn2+/A23187 system was 
similar to that observed for LUVs loaded using 
methylammonium sulfate (not shown). 
3.6. Removal of ionophores from LUVs 
Following drug uptake and in vivo administration, 
the presence of ionophores in LUVs is disadvanta- 
geous for two reasons. First, high serum concentra- 
tions of ions such as Na + and K ÷ may cause reverse 
transport with loss of the induced pH gradient. Sec- 
ond, ionophores are potentially toxic compounds, 
and therefore methods for reducing their concentra- 
tion are important. As ionophores will exchange be- 
tween vesicles [29], their removal should be relatively 
straightforward. We have developed a fluorimetric 
assay for determination of A23187 concentrations 
in formulations of SPM/Chol, which has allowed us 
to quantify the amount of ionophore before and 
after various treatments ( ee below). The potential 
for reducing nigericin concentrations has been as- 
sessed by examining the uptake of ciprofloxacin fol- 
lowing various treatments of an LUV sample. 
If a vesicle sample containing nigericin was passed 
down a spin column prior to loading with ciproflox- 
acin, the rate of uptake was significantly reduced, 
and the time to achieve similar uptake levels was 
Sample No. A23187 removal method Initial amount of A23187 (ng) Amount of A23187 measured (ng) 
S1 None 146 123 
$2 Sephadex G-50 column 109 n.d. a 
$3 Dialysis (1 h) 500 n.d. a 
$4 SM-2 biobeads 500 n.d. a 
$4+45 ng A23187 None 45 41 
$4+90 ng A23187 None 90 94 
aNot determined (number isat background levels (<- 15 ng)). 
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increased by a factor of 4 (Fig. 8A). This strongly 
suggests the removal of a significant proportion of 
the nigericin. If the LUVs containing nigericin were 
first subjected to dialysis (3 h), or if they were passed 
down a second spin column, similar uptake rates 
were observed, suggesting little or no further emoval 
of nigericin. Interestingly, the in vitro leakage rates 
of ciprofloxacin from normal and nigericin-reduced 
LUVs were found to be identical (data not shown). 
When LUVs containing nigericin were loaded with 
vincristine following exhaustive dialysis (room tem- 
perature for 20 h) and spin column treatment, he 
uptake levels at 1 h (60%) (Fig. 8B) were comparable 
to that obtained for ciprofloxacin using a single spin 
column (Fig. 8A). Taken together, these results sug- 
gest that nigericin can be partially removed from 
LUVs, but complete removal may not be feasible. 
The concentration of A23187 in LUVs can be 
quantitated using a fluorimetric assay (see Section 
2), that allows determination of the amount remain- 
ing following various purification procedures. The 
results are given in Table 3 for SPM/Chol LUVs 
initially containing A23187 at a concentration of 
0.1 gg/gmol lipid. For sample 1 (S1), 146 ng of 
A23187 was added to the LUVs, and 123 ng was 
measured by the assay. Following passage of the 
LUVs down a Sephadex G-50 column eluted with 
300 mM sucrose ($2), the remaining levels were be- 
low background. Likewise, dialysis against 300 mM 
sucrose ($3), or treatment with SM-2 biobeads ($4) 
reduced the A23187 concentration below back- 
ground levels. The addition of known aliquots of 
ionophore to $4 resulted in expected concentrations 
in the LUVs. The results demonstrate he surprising 
result that A23187 can be effectively removed from 
LUVs, in contrast to the incomplete removal ob- 
served with nigericin. 
3. 7. In vivo pharmacokinetics of liposomal 
ciprofloxacin and vincr&tine 
The pharmacokinetics of ciprofloxacin and vincris- 
tine loaded into SPM/Chol LUVs following injection 
into mice are shown in Fig. 9. Ciprottoxacin was 
loaded by the ionophore and methylammonium sul- 
fate methods (Fig. 9A), while vincristine was loaded 
using the standard pH gradient and ionophore meth- 
ods (Fig. 9B). Following injection into mice, samples 
were withdrawn at the indicated times, and the drug- 
to-lipid ratio of the recovered LUVs was determined. 
For ciprofloxacin (Fig. 9A), the A23187 system ex- 
hibited much superior etention than the K2SO4/ni- 
gericin system, and was similar to LUVs containing 
methylammonium sulfate. For vincristine (Fig. 9B), 
the retention observed for LUVs loaded using 
A23187 was comparable to LUVs loaded using 300 
mM citrate pH 4.0 [6--8]. This suggests that the effi- 
cacy achievable with LUVs loaded with drugs em- 
ploying the ionophore system should be comparable 
to either of the existing methods. 
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Fig. 9. In vivo retention of ciprofloxacin (A) and vincristine (B) 
in 100 nm SPM/Chol (55:45) LUVs. Drug-to-lipid ratios were 
determined following i.v. administration in mice of liposomal 
ciprofloxacin (A) containing 300 mM methylammonium sulfate 
(e), 300 mM MnSO4/A23187 (I), or 300 mM K2SO4/nigericin 
(•), or of liposomal vincristine (B) containing 300 mM citrate 
pH 4.0 (e) or 300 mM MnSO4/A23187 (11). Vincristine was en- 
capsulated ata drug-to-lipid ratio of 0.05, and measured using 
laH]vincristine as a tracer. Lipid was measured using 
[14C]cholesteryl hexadecyl ether as a tracer. The % retention is
defined as the drug-to-lipid ratio at time t divided by the initial 
measured drug-to-lipid ratio. 
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4. Discussion 
This paper describes a new method for loading 
weakly basic amines (a category which includes 
many pharmaceutically important drugs) into 
LUVs via transmembrane ion gradients. The method 
relies on the ionophore-mediated generation of a 
transmembrane pH gradient of 2-3 units (inside 
acidic) in response to a transmembrane ion gradient, 
and is based on the inward movement of protons 
which are coupled to the outward movement of met- 
al ions such as K ÷ or Mn 2+. 
The original ApH method, developed for loading 
doxorubicin, involves formation of the LUVs by ex- 
trusion in a citrate buffer (pH 4.0), and establishment 
of a pH gradient by passage down a column of Se- 
phadex G-50 equilibrated in HEPES-buffered saline 
(pH 7.5) [5]. The pH gradient (interior acidic) is 
formed prior to addition of the drug, and requires 
well-buffered internal and external solutions in order 
to achieve significant encapsulation and retention. 
One of the limitations of this method is revealed 
for drugs such as ciprofloxacin, which has very low 
solubility near neutral pH (< 0.4 mM at room tem- 
perature) [14]. 
An alternative method for ApH-dependent drug 
loading involves drug uptake in response to a secon- 
dary pH gradient established by a primary trans- 
membrane gradient of ammonium sulfate [15-17] or 
other amines [18]. This method has an advantage 
over the conventional method described above. As 
solutions are generally unbuffered, slightly acidic 
drugs such as ciprofloxacin can reduce the external 
pH to a value near or below 6, where solubility is 
higher. This method results in excellent uptake of 
ciprofloxacin and other drugs such as doxorubicin 
[15-171. 
In the present paper, we have examined rug up- 
take using two well-characterized ionophores, niger- 
icin and A23187. The method allows for rapid (5-15 
min) uptake of drug and excellent in vitro retention. 
Essentially complete uptake of ciprofloxacin and vin- 
cristine was achieved for both ionophores. One dif- 
ference between the two ionophores is the optimal 
external pH range for maximum uptake. For niger- 
icin, the highest uptake levels were achieved for 
pHo=5.5-6.0, whereas for A23187, the optimal 
range was pHo=6-7.5. Interestingly, the optimal 
pH for A23187-mediated transport of Ca 2+ and 
Mn 2+ is in the range of 6.7-7 [32,33], essentially 
identical to the pH maxima obtained for the trans- 
port of K + by nigericin [34]. 
A second difference between igericin and A23187 
is the necessity for an external chelator such as 
EDTA to achieve maximum uptake using A23187. 
Whereas uptake levels in the range of 80-100% are 
obtained with nigericin, only 20-50% uptake is ob- 
served for A23187 in the absence of EDTA com- 
pared with 95-100% in its presence. Insight into the 
differences between the two ionophores, specifically 
the requirement for a chelator in the case of A23187, 
can be gained using an elementary equilibrium anal- 
ysis of the transmembrane distributions of ionophore 
and ions. This analysis requires knowledge of the 
stoichiometry of the ionophore:divalent cation com- 
plex. While some studies support an A23187:Ca 2+ 
stoichiometry of 2:1 [29,32], others support a 1:1 
complex [35-40]. Furthermore, A23187 :Mn 2+ com- 
plexes appear to exist as mixtures of 2:1 and 1:1 
[32]. Both the 2:1 and 1:1 complexes have been ob- 
served in solution for several divalent cations [41]. In 
Appendix A, we treat both the 2:1 and 1:1 cases, 
and observe that the result is independent of the 
assumed complex stoichiometry, depending instead 
on the stoichiometry of MnZ+/H + transported. The 
key result, given in Eqs. A4 and A7 of Appendix A, 
details the relationship between the equilibrium pH 
and ion gradients. Thus, for nigericin (Eq. A4): 
[H+]i/[H+]o = [K+]i/[K+]o 
and for A23187 (Eq. A7): 
[H+]i/[H+]o = ([Mn2+]i/[ Mn2+]o)l/2 
This analysis reveals a direct relationship between 
the equilibrium pH gradient and equilibrium K + gra- 
dient generated by nigericin, i.e., in order to produce 
a ApH of 3 units (inside acidic), a K + gradient of 
1000:1 (inside:outside) must be generated. In con- 
trast, a square-root relationship exists between the 
equilibrium pH gradient and equilibrium Mn 2+ gra- 
dient generated by A23187, i.e., to achieve ApH = 3 
(inside acidic), a Mn z+ gradient of 106:1 (inside:out- 
side) must be generated. In other words, a much 
higher inside-outside concentration gradient of 
Mn 2+ must be maintained to maintain the same 
ApH. As a result, as Mn 2+ is transported out during 
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the drug loading process, the equilibrium ApH is 
rapidly reduced as the external Mn 2+ concentration 
rises. This compromises equilibrium drug loading 
levels, which for a drug containing a single amino 
function obeys the relation [Drug]i/[Drug]o =[H+]i/ 
[H+]o [1]. The presence of external EDTA alleviates 
this problem by binding external Mn 2+, thus main- 
taining extremely high Mn 2+ transmembrane concen- 
tration gradients. 
The requirement for EDTA may be further accen- 
tuated by retention of externally transported divalent 
cations in the vicinity of the membrane surface, due 
to the high affinities of divalent cations for mem- 
branes. For PC membranes, the affinity of cations 
follows the sequence M 3+ > M 2+ > M +, and whereas 
sizeable binding constants have been measured for 
Ca 2+, Mg 2+ and some lanthanides, the alkaline 
monovalent cations bind very weakly if at all 
[42,43]. A higher 'effective' ion concentration at the 
vesicle surface would further reduce the inside:out- 
side Mn 2+ gradient. Thus, EDTA is required to re- 
move Mn 2+ from the vesicle surface so as to main- 
tain an ion gradient sufficiently large to generate the 
requisite pH gradient. 
While both ionophores are capable of facilitating 
essentially complete uptake of ciprofloxacin and vin- 
cristine, and the loaded LUVs exhibit excellent reten- 
tion characteristics in buffer, the superiority of 
A23187-dependent loading is revealed by in vitro 
leakage assays (Fig. 7), and from the in vivo phar- 
macokinetics (Fig. 9). With respect o the in vitro 
studies, the Mn2+/A23187 system exhibits superior 
retention of ciprofloxacin (Fig. 7A) and vincristine 
(Fig. 7B). 
The in vivo pharmacokinetics of ciprofloxacin 
(Fig. 9A) reveal similar behavior as observed with 
the in vitro assay. The retention is dramatically bet- 
ter for the Mn2+/A23187 system than for K+/niger - 
icin, and is seen to be similar to LUVs loaded using 
methylammonium sulfate. For vincristine (Fig. 9B), 
the Mn2+/A23187 and standard ApH (internal cit- 
rate) [7,27] methods displayed comparable retention. 
As ionophores are potentially toxic compounds, 
we have examined means of removing them from 
vesicles. Using a fluorimetric assay, we have been 
able to show that essentially all of the A23187 can 
be removed from SPM/Chol LUVs by several meth- 
ods (Table 3), including gel exclusion chromatogra- 
phy, dialysis, and treatment with biobeads. Further, 
the results of uptake experiments strongly suggest 
that a portion of nigericin can also be removed. 
However, even if none of the A23187 was removed 
from the LUVs, the amounts used (approx. 20 gg/kg) 
would correspond to doses approx. 2 orders of mag- 
nitude below established toxic levels (LDs0 values 
range from 4500 gg/kg i.v. [44] to 9200 gg/kg i.p. 
[45]). Furthermore, the actual residual evels of ion- 
ophore (following removal) are more than 3 orders 
of magnitude below the lowest-observed-effect l vel 
of 11-15 gg/kg [45,46], where observed effects are 
mild. 
While toxicity concerns could also be raised for 
Mn 2+, they appear to be unwarranted at present. 
Most deleterious effects involve long term exposures 
[47-49]. Furthermore, in anticancer applications, the 
toxicity of Mn 2+ will be insignificant compared to 
that of the drug. Finally, several Mn-containing 
MR contrast agents are under development and ap- 
pear to pose no safety risk at doses up to 40 gmol/kg 
[50-53], which is in the same range as the ionophore 
system. If it becomes clear that Mn 2+ toxicity is a 
problem in some situations, the ion could be changed 
to Mg 2+ with no decrease in drug loading efficiency. 
Other ions, such as Fe z+ or Ba 2+, may also be pos- 
sible candidates for drug loading. 
Potential benefits of the ionophore loading method 
include, first, superior uptake and retention over the 
standard pH gradient echnique (especially for drugs 
such as ciprofloxacin, which has low solubility near 
neutral pH). Second, the ionophore method may 
allow higher absolute amounts of drug to be accu- 
mulated per mole of lipid. This is important, as it 
has been shown for drugs such as doxorubicin 
that the toxicity decreases at higher drug-to-lipid ra- 
tios [54]. Third, drug uptake, retention and efficacy 
may be improved by exploiting the tendency of 
many drugs to form complexes with divalent or tri- 
valent cations. Drugs in this category include doxo- 
rubicin [55-59], mitoxantrone [60], norfloxacin [61], 
ciprofloxacin [62], and daunorubicin [63]. The forma- 
tion of drug-metal complexes can lead to alterations 
in the biological activity of the drug, which may 
increase cytotoxicity. This has been demonstrated 
for complexes of doxorubicin with Fe 3+ and Cu 2+ 
[55-59,64-66]. The ionophore method can, therefore, 
potentially allow selection of divalent cations that 
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could function both in drug uptake and biological 
activity. 
In summary, we have described a new method for 
loading of LUVs via pH gradients induced by iono- 
phore-dependent ca ion transport. For both vincris- 
tine and ciprofloxacin, trapping efficiencies ap- 
proaching 100% are obtained, and the in vitro and 
in vivo retention is comparable to that observed us- 
ing other loading methods. Further work is required 
to determine whether higher drug-to-lipid ratios and 
improved retention can be achieved, and to deter- 
mine how the in vivo efficacy compares with LUVs 
loaded using the standard ApH and amine methods. 
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Appendix 
The relationship between equilibrium metal ion and pH 
gradients generated by ionophores: an elementary 
equilibrium analysis 
For nigericin-mediated K ÷ transport, our initial 
conditions consist of an LUV containing K2SO4. A 
nigericin molecule (N-) present on the inner mono- 
layer can bind a single K + ion, forming the mem- 
brane permeable neutral form NK, diffuse to the 
opposite side, and release the ion. The dissociation 
constant of the ionophore-metal complex, Kin, is giv- 
en by: 
gm = [N-][K+]/[NK] (ml) 
Potassium transport will continue until the concen- 
trations of the ionophore-K + complex on the inter- 
nal and external membrane surface are equal, i.e., 
until tNK]i - [NK]o. Assuming that Km,i = Km,o it fol- 
lows that 
[N-lo/[N-]i = [K+]i/[K+]o (A2) 
An analogous treatment for the transport of H + 
ions gives 
[N-]o/[N-]i = [H+]i/[H+]o (A3) 
Therefore 
[H+]i/[H+]o = [K+]i/[K+]o (A4) 
For A23187-mediated Mn 2+ transport, our initial 
conditions consist of an LUV containing MnSO4. 
For a 2:1 complex stoichiometry, two A23187 mol- 
ecules (A-) present on the inner monolayer can bind 
a single Mn 2+ ion, forming the membrane permeable 
neutral form MnA2, diffuse to the opposite side, and 
release the ion. The dissociation constant of the ion- 
ophore-metal complex, Km, is thus given by: 
gm = [Mn 2+] [m-]2/[Mnm2] (m5) 
Manganese transport will continue until the con- 
centrations of the ionophore-Mn 2+ complex on the 
internal and external membrane surface are equal, 
i.e., until [MnA2]i = [MnA2]o. Assuming that 
Km,i = Km.o it follows that 
[A-]o/[A-]i = ([Mn2+]i/[Mn2+]o) 1/2 (A6) 
As the equilibrium H + distributions are given by 
Eq. A3, it follows that 
[H+]i/[H+]o = ([Mn2+]i/[Mn2+]o)1/2 (A7) 
For the case of 1:1 complex stoichiometry, it is 
thought hat the 2:1 complex forms initially and dis- 
sociates to the 1:1 complex with the addition of fur- 
ther ion [41]. As the resulting MnA + species carries a 
+1 charge, it must co-transport an anion to give a 
neutral membrane-permeable species [32,41]. A likely 
candidate in the present case is OH-, as complexes 
of the form MA.OH have been observed in solution 
[41]. In this scenario, an A23187 molecule (A-) 
present on the inner monolayer can bind a single 
Mn 2+ ion, forming MnA +, which then interacts 
with a hydroxyl group to give the neutral complex 
MnA.OH, which diffuses to the opposite side, releas- 
ing the ion. The ionophore then binds a single pro- 
ton and returns to the vesicle interior. The external 
movement of the hydroxyl group is equivalent to the 
internal movement of a proton, and thus two H + are 
transported per Ca 2+, thereby preserving the ob- 
served electroneutrality [29]. The equilibrium can be 
written as: 
A- + Mn 2+ + H20 ~ MnA.OH + H + (A8) 
The dissociation constant of the ionophore-metal 
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complex, Kin, is thus given by: 
gm ~ [Mn2+][A- ] / [MnA-OH][H +] (m9) 
Manganese transport will continue until the con- 
centrations of the ionophore-Mn 2+ complex on the 
internal and external membrane surface are equal, 
i.e., until [MnA.OH]i- [MnA.OH]o. Assuming that 
Km,i-Km,o it follows that 
[A-]o/[A-]i---[Mn2+]i[H+]o/[Mn2+]o[H+]i (A10) 
It is straightforward to show that combining Eqs. 
A3 and A10 yields Eq. A7. Thus the relationship 
between the equilibrium transmembrane pH and 
ion gradients i the same regardless of the stoichiom- 
etry of the A23187-Mn 2÷ complex. 
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